FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility - MedCity News
The FDA has reversed its earlier stance and now supports uniQure's clinical data for its Huntington's disease gene therapy, AMT-130, allowing the company to proceed with a regulatory submission. This change reflects a shift in the FDA's approach under new leadership, emphasizing regulatory flexibility for rare disease treatments.
The recent FDA reversal allowing uniQure to pursue accelerated approval for its Huntington’s disease gene therapy, AMT-130, highlights a significant shift towards regulatory flexibility under the agency's new interim leadership. This change underscores the potential for more adaptive and patient-centric approaches in rare disease treatment approvals, especially when traditional clinical trial designs are impractical or unethical. For those tracking healthtech and biotech investments, this trend could signal increased opportunities for companies developing innovative therapies for rare and complex diseases.